Medtronic's fiscal 4th-quarter sales surge nearly 60% thanks to its buyout earlier this year of Covidien, prompting the medical device company to tighten its earning forecast.
A federal appeals court will not re-hear a decision dismissing a lawsuit filed over the alleged off-label use of Medtronic’s InFuse bone-growth protein.
Medtronic's Micra leadless pacemaker passes the initial safety and efficacy endpoints at the 1-month mark of a global clinical trial.
Data from a new study shows the noninferiority of cryoablation to standard ablation treatments for paroxysmal atrial fibrillation.
Cryoablation is as effective as radio-frequency ablation in treating paroxysmal atrial fibrillations, researchers reported today at the Heart Rhythm Society’s annual meeting in Boston.
Medtronic's Evera MRI SureScan implantable cardioverter defibrillator meets the safety and efficacy endpoints of the 1st randomized trial of an MRI-safe ICD.
The newest version of Medtronic's Arctic Front cryoballoon has won approval for use in treatment of paroxysmal atrial fibrillation.
Medtronic (NYSE:MDT) said it won FDA approval for its Arctic Front Advance ST cryoablation catheter for treating atrial fibrillation, touting a 40% shorter tip than previous versions.
Here's a look at some of the top regulatory stories for medical device companies this week: FDA withdraws older guidance documents; Medtech panel: Good news-bad news on FDA, value-based healthcare; Medtronic launches new spine devices; FDA warns Smith & Nephew on Truclear Ultra morcellator; FDA clears Medtronic's Euphora balloon